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Abstract Background: To determinewhetheripratropiumwas associatedwithpremature deathinpatientswith asth-
ma and chronic obstructive pulmonarydisease (COPD).Methods:Alongitudinal cohortof 827 patientswith COPDand
273 with asthmawhowere evaluated for compensation by two specialists in pulmonarymedicine. Results: By June1999,
538 ofthe patientswith COPDand 77 ofthosewith asthmahaddied.Atthe consultation,7.7% ofthe COPD patients and
8.1% of the asthmatic patients were treated with inhaled ipratropium. Ipratropium was associated with mortality,
risk ratio (RR) of 2.0 (95% confidence interval:1.5^2.6) for COPD and 3.6 (1.8^7.1) for asthma patients. After adjustment
for confounding factors [forced expiratory volume 1s (FEV1), smoking habits, asthma medication, and presence of
cor pulmonale] the RR for COPD was 1.6 (1.2^2.1) and for asthma 2.4 (1.2^5.0). Conclusions: The increased risk of
premature death associated with ipratropium is of concern and necessitates further evaluation, e.g., in a randomised
study.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
Keywords COPD; asthma; survival; ipratropium.Two recent retrospective studies of patients admitted
to hospital with asthma showed that treatment with
ipratropium at discharge was associated with an in-
creased risk of death (1,2). These ¢ndings raise the di⁄-
cult question as to whether ipratropium is a marker of
severe disease or whether ipratropium is a risk factor
in its own right. In the studyby Sin and Tu (2), the slightly
increased mortality in chronic obstructive pulmonary
disease (COPD) patients treated with ipratropium be-
came insigni¢cant after adjustments for severity of dis-
ease, age, and sex. Although attempts to adjust for
severity of obstructive lung disease have been done,
neither of the studies has controlled for forced expira-
tory volume in 1s (FEV1), pack-years of tobacco, body
mass index (BMI), breathlessness, and concomitant
chronic bronchitis and ischaemic heart disease which
are all predictors of survival in COPD patients and, to
some extent, in asthmatic patients (3^10). Therefore,
the association in asthmamight still be explainedby resi-
dual confounding by disease severity. We conducted aReceived 23 April 2002, accepted in revised form 22 July 2002
Correspondence should be addressed to:DrThomas Ringbaek,
Krogebakke 2 B,DK-3140 Aalsgaarde,Denmark.
E-mail: ringbaek@dadlnet.dkstudy of outpatients with asthma or COPD and evalu-
ated the association of ipratropium prescription and
mortality, including a panel of known potential confoun-
ders.
METHODS
From1977 to1997, approximately 2200 patientswith pul-
monary symptoms were referred to two specialists in
pulmonary medicine for medical evaluation of disability.
Before the patients were evaluatedF always as outpa-
tientsFmost of them had been in contact with a spe-
cialist practice or a hospital.Before the evaluationby the
pulmonary specialists, most of the patients had a rever-
sibility test with inhaled beta2-agonists and some with
oral corticosteroids. If the result of such a test was
ambiguous or had not been performed, a reversibility
test using 2mg terbutaline from an inhalator was admi-
nistered (48.1% of the patients). COPD was de¢ned as
FEV1 o80% of predicted value, an FEV1/FVC-ratio
o70%, and exclusion of other obstructive airway dis-
eases such as asthma and bronchiectasis. The two pul-
monary specialists made the diagnosis after a careful
evaluation including a ¢le of previous examinations as
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reversibility tests and frequently additional tests (TLC in
48.5% and di¡usion capacity in 1.7%). Some of the asth-
matic patients with chronic airway limitation may have
concomitant COPD as well. In this study, the asthma di-
agnosiswasused if thepatienthad any asthmatic compo-
nent including an absolute increase in FEV1 4250ml
after beta2-reversibility test. All patients were
asked the same questions and had FEV1 and forced
vital capacity (FVC) measured with a spirometer
(Vitalograph; Ennis, Ireland).The patients were included
in the routine of the pulmonary outpatient clinic,
where a special nurse under supervision of a medical
doctor maintained the Vitalographs. Tests with cali-
brated 1 and 3 l syringes were performed weeklyFand
if suspicion of malfunction arose. The calibration of the
Vitalograph showed the valuesmeasured to be the same
year after year. Routine procedure for spirometry was
to perform at least three curves. If they did not show
reproducibility, testing was continued until reproducible
curves were obtained. The best FEV1 and FVC have
been used.
The study comprised 1100 subjects with obstructive
pulmonary disease. COPD was diagnosed in 827 cases
and asthma in 273 cases. A total of 67 COPD patients
were excluded, two because of lack of information on
medical treatment and 65 patients with no information
on smoking history, FEV1, or BMI. The number of pack-
years of tobacco was calculated (1 cigarette= 1g, 1 che-
root= 3.5g, 1 cigar=5g, pipe tobacco: actual number of
grams). Patients gave information on actual alcohol con-
sumption. They were classi¢ed with a positive alcohol
history, if they had ever been treated with disulph¢ram,
hadbeen hospitalised due to abuse of alcohol, or had any
family catastrophes related to alcohol (divorce, family
violence, and loss of work or crimes due to alcohol in-
take).
As ischaemic heartdisease is a frequentcontributor of
pulmonary symptoms in tobacco smokers, this disease
hasbeenreported aswell. Adiagnosis of ischaemic heart
diseasewas based on the previous ¢les and from the his-
tory and the physical examination obtained by the pul-
monary specialist, a diagnosis of ischeamic heart disease
wasmade.Themedical treatmentof thepatientswas re-
gistered but was not supposed to be interfered with.
This should be done by the patient’s own physician. As
patients were investigated during stable medical condi-
tion, treatmentwith ipratropiumwas not a part of treat-
ment of an exacerbation. In Denmark, like most other
countries, ipratropium has been considered a secondary
drug in asthma treatment and a ¢rst line drug together
with beta2-agonists in COPD patients.
The number of COPD and chronic bronchitis patients
with ipratropium increased from 5.2% during 1977^1983
to 8.9% during 1984^1989 and levelled o¡ (10.2%) during
1990^1996.The National Health Services Central Register ascer-
tained vital status until June1st,1999.Themean follow-up
periodwas13.1years (range 2.5^22.4 years) duringwhich
time 614 deaths were identi¢ed among the1100 patients.
Seven COPD have emigrated; survival until emigration
was included. In 610 patients (99%), the cause of death
was obtained from the death certi¢cate and in 187
(30.7%), an autopsy was performed (29% among those
who died from obstructive lung disease). The causes of
death were categorised into seven groups: (1) obstruc-
tive lung disease, (2) lung cancer, (3) extra-pulmonary
cancer, (4) cardiovascular disease, (5) other pulmonary
diseases, (6) accidents, poisoning or suicide, and (7)
others. Three patients who died accidentally were not
included in the calculation of risk ratios.
STATISTICS
Data analysis and descriptive statistics were performed
with the statistical package for the social sciences (SPSS)
ver.11.0 (SPSS Inc.,Chicago,U.S.A.).Cox proportional ha-
zards regression was used to determine whether ipra-
tropium was associated with increased mortality from
all causes, obstructive lung disease, lung cancer, extra-
pulmonary cancer, and cardiovascular disease, respec-
tively.The hazard ratios [relative risks (RR)] were calcu-
lated for the following covariates: age, gender, FEV1
%predicted (o40, 40^59, 60^79, and 80), BMI (o20,
20^24.9, 25^29.9, and 30kg/m2), pack-years of smoking
(0, 1^19, 20^39, and 40), smoked tobacco at evaluation
(0, 1^14, and 15g/day), alcohol consumption (0^2, 3^5,
6^8, and 9 drinks), alcohol history F yes/no, treat-
ment with prednisoloneF yes/no, inhaled corticoster-
oidF yes/no, beta2-agonistF yes/no, and theophylline
F yes/no, dyspnoea on e¡ortF yes/no, at restF yes/
no, and during nightF yes/no, attacks of dyspnoeaF
yes/no, co-morbidity from ischaemic heart disease F
yes/no, chronic bronchitisF yes/no, and cor pulmonale
F yes/no, and ¢nally time period of entrance (1977^
1983, 1984^1989, and 1990^1996). Time period of en-
trancewas includedbecause a signi¢cantly lowernumber
of patients were treated with ipratropium in the early
period (1977^1983) as compared to the latest period.
The hazard ratios for ipratropium treatment were ad-
justed for those covariates, whichwere related to death
and to ipratropium; i.e., true confounders.
Continuous variables were transformed into standar-
dised categories as listed above if linearity was not
present. Assumption of linearity was assessedby categor-
ising the variable into multiple dichotomous variables of
equal units on the variable’s scale. The estimated coe⁄-
cients of each dichotomous variablewere compared.
All co-variates were tested for interaction with ipra-
tropium. Estimates of survival curves among patients
with and without ipratropium were done using the
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tientswith COPD and asthma separately. A two-sided P-
value ofo0.05 was considered signi¢cant.
RESULTS
The characteristics and the medical treatment are
shown for patients with COPD and asthma inTable1.
COPD patients
FEV1was less than 40% of predicted value in 374 (45.2%).
Only 25 (3.0%) had never smoked tobacco, and 612
(74.0%) were current smokers. A BMI o20kg/m2 was
found in 159 (19.2%) of the patients. During follow-up,TABLE 1. Characteristics of patientswith COPDand asthma ac
COPD
+Ipr. (n=64)
Gender female (%) 45.3
Age (years) 55.6(9.1)
FEV1 (% predicted) 35.5(11.6)
BMI (kg/m2) 24.3(5.3)
Pack-years 35.5(0^75)
Smoking status (%)
Neveror former smokers 35.9
1^14 g tobacco/day 15.6
15 g tobacco/day 48.4
Alcoholhistory (%) 17.2
Alcohol consumption (%)
0^2 drinksperday 82.0
3^5 drinksperday 14.8
6^8 drinksperday 14.8
9 drinksperday 3.3
Chronic bronchitis (%) 84.4
Dyspnoea on e¡ort (%) 100
Attackof dyspnoea (%) 28.1
Dyspnoea at rest (%) 6.3
Nocturnal dyspnoea, % 26.6
P.o. prednisolone (%) 17.2
Inhaled steroid (%) 35.9
Beta2-agonist (%) 79.7
Theophylline (%) 48.4
Ischemic heartdisease (%) 10.9
Corpulmonale (%) 9.4
Period of entrance, %
1977^1983 26.6
1984^1989 40.6
1990^1996 32.8
Age,FEV1, and BMI are presented asmean (SD), andpack-year
*P40.05.
**Po0.05.
***Po0.01.538 of the COPD patients (65.1%) died. The 5- and 10-
year mortality rates for these patients were 26.6 and
49.2%, respectively (Fig.1).
Treatment with inhaled ipratropium was associated
with an increasedmortality from all causes.The RRwas
2.0 [95% con¢dence interval (CI) 1.5^2.6] in the crude
analysis and1.6 (1.2^2.1) after adjustment of confounders
(Tables 2 and 3).
Almosthalf, 242 (45.0%), of the deathswere registered
as caused by obstructive pulmonary disease (with 20 of
these registered as asthma), 59 (11.0%) by lung cancer, 47
(8.7%) by extra-pulmonary cancer,116 (21.6%) by cardio-
vascular disease, 37 (6.9%) by other pulmonary diseases,
21 (3.9%) by accidents, poisoning, or suicide, and16 (3.0%)
by other diseases. The increased mortality from all
causes observed in patients with inhaled ipratropiumcording to treatmentwith inhaled ipratropium.
Asthma
-Ipr (n=763) +Ipr (n=22) -Ipr (n=251)
43.3* 50.0 62.2*
56.7(7.8)* 49.9(8.1) 47.1(11.2)*
44.9(16.7)*** 56.7(20.9) 68.4(21.4)**
25.0(5.7)* 27.8(6.8) 25.7(4.8)*
33(0^99)* 20(0^50) 9(0^66)***
25.2* 36.4 57.8*
24.4* 27.3 24.3*
50.5* 36.4 17.9**
13.1* 9.1 9.6*
77.4* 90.5 91.4*
13.8* 9.5 3.7*
4.5* 0.0 3.3*
4.3* 0.0 1.6*
84.7* 13.6 17.5*
97.0* 90.9 81.7*
14.8*** 81.8 77.7*
5.4* 0.0 6.8*
13.1*** 59.1 47.4*
4.8*** 54.5 13.9***
16.4*** 68.2 61.8*
55.2*** 95.5 86.5*
29.6*** 27.3 42.6*
7.1* 0.0 1.2*
4.1** 0.0 0.8*
41.0** 22.7 34.3*
34.9* 36.4 37.5*
24.1* 40.9 28.3*
s andpresentgrams oftobacco asmedian (range).
INHALEDIPRATROPIUMANDMORTALITY 267was derived from an increased risk of COPD death, and
lung cancer death, whereas the rates of cardiovascular
deaths andextra-pulmonarycancerwerenot associated
with treatment of inhaled ipratropium (Table 3). Com-
pared to patients without theophylline and beta2-ago-
nists, a tendency towards an increased risk was found
in patients treated with both theophylline and beta2-
agonists (RRs 1.5 and 2.4, respectively; P-value = 0.38)
(Table 4).
Asthma patients
A normal FEV1 (80% of predicted) was seen in 82
(30.0%) of the patients and only 32 (11.7%) had an FEV1
less than 40%. Less than half of the patients (120=44.0%)
were current smokers and 78 (28.6%) had never smoked
tobacco. Only 23 (8.4%) of the patients had a BMI
o20kg/m2.Nearly one-third, 77 (28.2%), of the asthma
patients died during follow-up. The primary cause
was asthma in 15 (19.5%) cases and COPD in 18 (23.4%)40
Su
rv
iv
al 
pr
ob
ab
ili
ty
1.0
0.8
0.6
0.4
0.2
0
with ipr., deaths: 0      23              4
    alive: 64      39              1
without ipr., deaths: 0    155  30
   alive: 763    584             37
with
ipratrop
FIG. 1. Unadjusted survival among COPD patientswith andwithou(Table 3).The 5- and10-year mortality rates for patients
with asthma were 5.9 and17.6%, respectively (Fig. 2). As
in COPD, treatment with inhaled ipratropium increased
mortality from all causes in asthmatic patients. The un-
adjusted RR was 3.6 (1.8^7.1), and after adjustment the
RR decreased to 2.4 (1.2^5.0).
Nearlyhalf of the deaths, 33 (42.9%),wereregistered as
causedby either asthma (16) or COPD (17), four (5.2%) by
lung cancer, 12 (15.6%) by extra-pulmonary cancer, 13
(16.9%) by cardiovascular disease, two (2.6%) by other
pulmonary diseases, ¢ve (6.5%) by accidents, poisoning,
or suicide, and eight (10.4%) by other diseases. The
increased risk of using ipratropium was due to a
markedly increased risk of dying of obstructive lung
disease, whereas the risk of dying from lung cancer and
extra-pulmonary cancer was lower and statistically insig-
ni¢cant (Table 3). A calculation of the estimated RRof dy-
ing from cardiovascular disease if treated with
ipratropium was not possible since none of the patients
with ipratropium had died from cardiovascular disease.
Compared to patients with either theophylline or242016128
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t ipratropium (Ipr.) treatment, respectively.
TABLE 2. Relative risks of death in COPDand asthma patients.
COPD Asthma
Ipratropium, (no=1) 2.0 (1.5^2.6) 3.6 (1.8^7.1)
FEV1 (% predicted)
80 Not included 1
60.0^79.9 1 4.1 (1.6^10.6)
40.0^59.9 1.81.4^2.5) 4.9 (1.9^12.9)
o40 3.6 (2.8^4.8) 11.0 (4.2^29.1)
Pack-years,
0 1
0.1^19.9 1.2 (0.6^2.4)
20.0^39.9 3.3 (1.8^6.1)
40 4.1 (1.7^9.9)
Smoking status
Neveror former smokers 1
1^14 g tobacco/day 1.8 (1.0^3.0)
15 g tobacco/day 2.4 (1.3^4.2)
P.o. prednisolone (no=1) 1.7 (1.2^2.4) 2.2 (1.3^3.6)
Beta2-agonist (no=1) 1.2 (1.0^1.4)
Theophylline (no=1) 1.4 (1.2^1.7)
Corpulmonale (no=1) 2.6 (1.9^3.7)
Only statistically signi¢cant factors are shown (meaningful confounders ofthe relationship of ipratropiumand survival).
The RRs are calculated froma univariate logistic regression analysis.Three patientswho died accidentally are excluded.
95% con¢dence interval in parentheses.
TABLE 3. Deaths from obstructive lung disease (asthma or COPD), lung cancer, extra-pulmonale cancer, cardiovascular dis-
ease, and all causes by ipratropiumtreatment (Ipr.) atevaluation in COPDand asthma patients, respectively
COPD Asthma
Cause of death No. at risk Deathsper1000
observation
years (no.)
RR (95% CI)
adjusteda
No. at risk Deathsper1000
observation
years (no.)
RR (95% CI)
adjustedb
All causesc
Without Ipr. 761 78.8(487) 1 251 24.0 (66) 1
With Ipr. 64 138.5(49) 1.6(1.2^2.1) 21 71.0(10) 2.4(1.2^5.0)
Obstructive lungdisease
Without Ipr. 761 34.1(211) 1 251 9.8(27) 1
With Ipr. 64 87.6(31) 2.0(1.3^2.9) 21 42.6(6) 3.4(1.2^9.3)
Lungcancer
Without Ipr. 761 8.1(50) 1 251 1.1(3) 1
With Ipr. 64 25.4(9) 3.5(1.6^7.3) 21 7.1(1) 3.0(0.1^59.6)
Extra-pulmonarycancer
Without Ipr. 761 7.3(45) 1 251 4.0(11) 1
With Ipr. 64 5.7(2) 1.0(0.2^4.0) 21 7.1(1) 2.1(0.2^18.0)
Cardiovasculardisease
Without Ipr. 761 18.0(111) 1 251 4.7(13) 1
With Ipr. 64 14.1(5) 0.7(0.3^1.7) 21 0(0) Not applicable
Ipr.: ipratropium;RR: relative risk from a Cox analysis;CI: con¢dence interval. aAdjusted for FEV1, prednisolone, beta2-ago-
nist, theophylline, and cor pulmonale.badjusted for FEV1, %predicted, pack-years, smoking status, andprednisolone.
cThree patientswho died accidentally are excluded.
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TABLE 4. The risks of dying in COPD and asthma patients treatedwith ipratropium (Ipr.) alone or in combinationwith other
bronchodilators.
COPD Asthma
No. of deaths
without Ipr./at
risk
No. of deaths
with Ipr./at
risk
Adjusteda
RR (95% CI)
No. of deaths
without Ipr./at
risk
No. of deaths
with Ipr./at
risk
Adjustedb
RR (95% CI)
Neither beta2-agonists nor
theophylline; reference:
without Ipr.
164/263 5/7 1.5 (0.6^3.6) 3/15 1/1 Not applicable
Beta2-agonistor
theophylline; reference:
without Ipr.
214/351 20/32 1.1 (0.7^1.8) 41/148 8/15 2.5 (1.0^6.2)
Bothbeta2-agonists and
theophylline; reference:
without Ipr.
109/147 24/25 2.4 (1.5^3.8) 22/88 1/5 1.7 (0.2^15.1)
RR: relative risks froma Cox analysis;CI: con¢dence interval.
aadjusted for FEV1, prednisolone, beta2-agonist, theophylline, and cor pulmonale.
badjusted for FEV1, %predicted, pack-years, smoking status, andprednisolone.
Three patientswho died accidentally are excluded.
INHALEDIPRATROPIUMANDMORTALITY 269beta2-agonists, aweak tendency towards a decreasedrisk
was found in patients treated with both theophylline and
beta2-agonists; however, the number of patients are low
(P=0.14) (Table 4).
DISCUSSION
In our study, prescription of ipratropiumwas associated
with increased mortality in both COPD and asthmatic
patients.We found a higher risk in both COPD patients,
adjusted RR: 1.6 and in asthma patients, 2.4 compared
with the study by Sin and Tu, RRs:1.03 and1.24 (2). In the
latter study, only patients aged 65 years or more were
included. Guite and co-workers studied risk factors for
death among asthmatics aged16^64 years (1).They found
a 2.9-fold RR of dying when patients were prescribed
ipratropium or salbutamol^ipratropium.This increased
risk was based on a signi¢cant increased risk of dying
from asthma.
Our studydi¡ers from the two others in severalways.
First of all, we included patients referred to pulmonary
specialists for evaluation of disability contrary to hospi-
tal-admitted patients in the other studies (1,2). Secondly,
we were able to make adjustments for several known
risk factors; e.g., FEV1%, smoking status, BMI, and dys-
pnoea. Instead, the above-mentioned studies had cor-
rected for other factors; e.g., health service visits1year
prior to study entry (2), and a history of clinically severe
asthma, and hypercapnia during hospitalisation at study
entry (1).Our patientswhowere given ipratropiumwere
more severe than those who were not. Therefore, ouradjustments for severity reduced the association in
COPD patients in COPD, from 2.0 to 1.6, and in asthma
patients, from 3.6 to 2.4. Still, we cannot rule out bias
due to unmeasured confounding; e.g., residual confound-
ing by disease severity.None of the studies have adjusted
for blood eosinophilia or use of psychotropic drugs,
which aremarkers of riskof asthma death (7,11).Norhave
the studies adjusted fordi¡using capacity andbloodgases
with the patient in a clinically stable condition, variables,
which are predictors of premature COPDmortality (12).
In a study of asthma deaths, patients prescribed psycho-
tropic drugs had a 3.7-fold RR of dying, but prescription
of these drugs was not associated with prescription of
fenoterol, and therefore the RR for fenoterol remained
unaltered (11,13). Among our COPD patients, predniso-
lone, beta2-agonist, and theophylline were associated
with increased risk of dying in the crude analysis, but
not in the adjusted model, suggesting that ipratropium,
contrary to theophylline and prednisolone, is more than
a marker of disease severity.
To ensure proper adjustment for disease severity, one
has to employ a randomised and controlled design. In or-
der to evaluate the e¡ectof smoking cessation anduse of
ipratropium on decline of FEV1, The Lung Health Study
included patients with mild COPD in a randomised and
controlled design (14). After a 5-year follow-up, 54
patients in the ipratropium group had died compared
with 44 in the placebo group (P-level for di¡erence:
0.08). So, in this subgroup of mild COPD patients, ipra-
tropium did not increasemortality.
In contrast to ordinary patients from an outpatient
clinic, our patients were referred for medical evaluation
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FIG. 2. Unadjusted survival amongasthma patientswith andwithout ipratropium (Ipr.) treatment, respectively.
270 RESPIRATORYMEDICINEof disability.When the evaluation could result in approval
or denial of disabilitybene¢ts, patientsmay tend to exag-
gerate their symptoms and minimise risk factors invol-
ving their behaviours such as smoking and drinking. In
our studyofCOPDpatients, however, neither symptoms
nor behaviours were confounders, and among asthma
patients the present number of smoked cigarettes were
only weakly associatedwith survival, suggesting that any
misstatementwould have little in£uence on the adjusted
RR of dying from ipratropium.
In the discussion of an associationbetween a predictor
andpremature death, onehas to bear inmind that all po-
tential predictors were only evaluated at the time of the
referral.Patientsmighthave changed smoking status and
treatment later on. Another limitation of this study is
the fact that the dose of ipratropium and prednisolone,
and the duration of treatmentprior to the evaluationhas
not been considered.We have only been able to look at
anydosevs. none. In COPDpatients, a tendency towards
an increased risk was found in those treated with both
theophylline and beta2-agonists. Ipratropium users were
more frequently prescribed prednisolone. Our adjust-ment for use of prednisolone as ‘‘yes’’ or ‘‘no’’ may not
provide a fully su⁄cient adjustment for di¡erences in this
marker of severity and risk of death. Death risk is
increased in patients with ‘‘brittle asthma’’. Some of the
characteristics of thesepatients are overuse ofbroncho-
dilators, nearly normal spirometry, and undertreatment
of corticosteroids.Our ¢nding of an increasedmortality
among ipratropium users was not related to any of the
above-mentioned characteristics.
What are the possible explanations for an increased
death rate in patients treated with ipratropium? Similar
to Guite et al. (1), the highest risk estimate among
the asthma patients was found for deaths due to
obstructive lung disease in our study. Guite et al. sug-
gested that the drying e¡ect that ipratropium has on
lung secretions might lead to mucus plugging, but the
frequency of autopsies in their study and ours was
too low to evaluate this hypothesis (1). In established
mild COPD, ipratropium does not change the decline in
FEV1 compared with placebo (14). An increased risk of
dying from cancer was observed among our COPD
patients with ipratropium. The most likely explanation
INHALEDIPRATROPIUMANDMORTALITY 271for this association is residual confounding from tobacco
smoking.
In contrast to the study of Guite et al., we were not
able to ¢nd anincreasedriskof dying fromcardiovascular
disease (1). In the Lung Health Study, signi¢cantly more
patients with ipratropium died from cardiovascular dis-
ease, but this was after a careful evaluation interpreted
as a coincidence (14). In the studyby Sin and Tu, their ana-
lyses were restricted to all-causemortality (2). In gener-
al, the number of asthmatic patients with ipratropium in
our and Guite’s study was too low to give a clear answer
on causes of increasedmortality.
The proportion of patientswhowere prescribed ipra-
tropium in the two retrospective studies (1,2) showing a
relationship between ipratropium and premature mor-
tality in asthmatic patients was 30^50%, which is high
and indicates that caution should be taken when inter-
preting these ¢ndings. According to another Canadian
study focusing on prescription of drugs used in airway
managementduring1985^1990, theproportion of COPD
and asthma patients with ipratropium was only
3^7% (15). In a study from Auckland evaluating the
e¡ect of fenoterol on mortality, 12% of the patients
had either ipratropium alone or in combination with
fenoterol (16).
Several parallels can be drawn to the previous debate
on fenoterol, discussing whether fenoterolwas amarker
of severe disease or whether therewas a causal relation-
ship between fenoterol and increased mortality
(8,11,13,16,17). Surprisingly, only one of these studies has
presented data on the relationship between ipratropium
andmortality (16). In a crude analysis, users of a lowdose
of fenoterol in combination with ipratropium had the
highest RR estimate for severe life-threatening asthma
and death [RR=2.8 (95% CI 1.4^5.5)] when compared
with inhaled salbutamol.
Misclassi¢cation of COPD and asthma is a known pro-
blemFespecially among elderly. A separation of asthma
from COPD is based on several clinical parameters. In
our study, data on smoking history, symptoms (attack of
dyspnoea, nocturnal dyspnoea and chronic bronchitis),
and use of inhaled steroid support a correct separation
in most cases. An asthmatic patient can later die from
COPD and vice versa. In our study of asthma patients,
the proportion of deaths from obstructive lung disease
due to COPD was 57.1%.This increase in the proportion
of deaths from COPD accords with previous ¢ndings
(18^20). Recognising this problem of misclassi¢cation,
others have avoided this separation and pooled deaths
from COPD and asthma (21,22). When the association
between ipratropium and mortality was signi¢cant in
both COPD and asthma patients, any misclassi¢cation
would only increase the risk for one subgroup at the ex-
pense of the other subgroup.
In conclusion, our results support a relationship be-
tween ipratropium andpremature death in patientswithobstructive lungdiseaseF especially among asthmatics.
In order to establish a potential causal relationship, a
prospective randomised study comparing a beta2-ago-
nist with ipratropium in patients with severe COPD and
asthma seems a necessary next step.
REFERENCES
1. Guite HF, Dundas R, Burney PGJ. Risk factors for death from
asthma, chronic obstructive pulmonary disease and cardiovascular
disease after a hospital admission for asthma. Thorax 1999; 54:
301–307.
2. Sin DD, Tu JV. Lack of association between ipratropium bromide
and mortality in elderly patients with chronic obstructive airway
disease. Thorax 2000; 55: 194–197.
3. Rosengren A, Wilhelmsen L. Respiratory symptoms and long-
term risk of death from cardiovascular disease, cancer and other
causes in Swedish men. Int J Epidemiol 1998; 27: 962–969.
4. Landbo C, Prescott E, Lange P, etal. Prognostic value of nutritional
status in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 1999; 160: 1856–1861.
5. Speizer FE, Fay ME, Dockery DW, et al. Chronic obstructive
pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis
1989: 140: S49–S55.
6. Tockman MS, Comstock GW. Respiratory risk factors and
mortality: longitudinal studies in Washington county, Maryland.
Am Rev Respir Dis 1989; 140: S56–S63.
7. Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma
death among 1075 outpatients with asthma. Chest 1995; 108:
10–15.
8. Ryan G, Musk AW, Perera DM, et al. Risk factors for death in
patients admitted to hospital with asthma: a follow-up study. Aust
NZJMed 1991; 21: 681–685.
9. Krzyzanowski M, Wysocki M. The relation of thirteen-year
mortality to ventilatory impairment and other respiratory
symptoms: the Cracow study. Int J Epidemiol 1986; 15: 56–64. .
10. Lange P. Groth S, Nyboe J, et al. Chronic obstructive lung disease
in Copenhagen: cross-sectional epidemiological aspects. J Int Med
1989; 226: 25–32.
11. Crane J, Pearce N, Burgess C, et al. Markers of risk of asthma
death or readmission in the 12 months following hospital
admission for asthma. Int J Epidemiol 1992; 21: 737–744.
12. Gray-Donald K, Gibbons L, Shapiro SH, et al. Nutritional status
and mortality in chronic obstructive pulmonary disease. AmJRespir
Crit Care Med 1996; 153: 961–966.
13. Grainger J, Woodman K, Pearce N, etal. Prescribed fenoterol and
death from asthma in New Zealand, 1981–7: a further case–
control study. Thorax 1991; 46: 105–111 .
14. Anthonisen, NR, Connett JE, Kiley JP, et al. Effects of smoking
intervention and the use of an anticholinergic bronchodilator on
the rate of decline of FEV1. The Lung Health Study. JAMA 1994;
272: 1497–1505.
15. Kesten S, Rebuck AS, Chapman KR. Trends in asthma and chronic
obstructive pulmonary disease therapy in Canada, 1985 to 1990. J
Allergy Clin Immunol 1993; 92: 499–506.
16. Garrett JE, Lanes SF, Kolbe J, et al. Risk of severe life threatening
asthma and b agonist type: an example of confounding by severity.
Thorax 1996; 51: 1093–1099.
17. Spitzer WO, Suissa S, Ernst P, etal. The use of b-agonists and the
risk of death and near death from asthma. NEngl JMed 1992; 326:
501–506.
18. Alderson M, Loy RM. Mortality from respiratory disease at
follow-up of patients with asthma. Br J Dis Chest 1977; 71:
198–202.
272 RESPIRATORYMEDICINE19. Markowe HLJ, Bulpitt CJ, Shipley MJ, et al. Prognosis in adult
asthma: a national study. BMJ 1987; 295: 949–952.
20. Lange P, Ulrik CS, Vestbo J. Mortality in adults with self-reported
asthma. Copenhagen City Heart Study Group. Lancet 1996; 347:
1285–1289.21. Huovinen E, Kaprio J, Vesterinen E, et al. Mortality of adults with
asthma: a prospective cohort study. Thorax 1997; 52: 49–54.
22. Ulrik CS, Backer V, Dirksen A. Mortality and decline in lung
function in 213 adults with bronchial asthma: a ten-year follow up.
J Asthma 1992; 29: 29–38.
